Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc > COTI 219

<< Previous

Bullboard Posts

Next >>

Comment by Actuarialon Jul 28, 2017 9:44am

82 Views

Post# 26520864

RE:COTI 219

It took Kevetrin three years to complete phase 1 (August 2, 2012 - Feb 23, 2016) and similar time for Apr-246. COT was too optimstic on setting phase 1 completion time, which is their first mistake. COT did reverse split without positive news following the split, which is their second mistake. Comparing with their mistakes, our mistake is much bigger. We should have run when Danter resigned.

<< Previous

Bullboard Posts

Next >>

Golden Minerals closes Yoquivo gold-silver project sale